|November 5, 2018
AMA Urges FTC to Act on Insulin Prices
[from AMA Advocacy Update]
The AMA expressed strong concern to the Federal Trade Commission (FTC) in an Oct. 26 letter
about the sharp rise in insulin prices among manufacturers. The AMA
urged the agency to monitor insulin pricing and assess whether
anti-competitive actions were driving higher insulin prices.
In addition,Modern Healthcare (11/1, Luthi, Subscription Publication) reports that Reps. Tom Reed (R-NY) and Diane DeGette (D-CO) are asking Congress “to limit patent extensions which have allowed insulin manufacturers to stop new generics from entering the market” in order to address rising insulin costs. According to their analysis, “Experts predict that follow-on insulins could cost 20 to 40 percent less than their brand name equivalents, creating savings for patients.” The article says other proposed changes include a proposal for “PBMs and health plans to disclose how many rebates they receive and pass along,” as well as “banning the ‘pay-for-delay’ practice in which the expired patent-holding brand drug maker pays a generic manufacturer not to produce the off-patent drug.”
< Previous Article | Next Article >
[ return to top ]
ensure delivery of Maine Medicine Weekly Update,
please add 'firstname.lastname@example.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details: http://www.commpartners.com/website/white-listing.htm
For more information or to contact us directly, please visit www.mainemed.com | ©